Back to Search Start Over

Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma.

Authors :
Mohan AC
Venkatramani R
Okcu MF
Nuchtern JG
Vasudevan SA
Mahajan A
Rainusso NC
Allen-Rhoades W
Chintagumpala M
Paulino AC
Source :
Pediatric blood & cancer [Pediatr Blood Cancer] 2018 Feb; Vol. 65 (2). Date of Electronic Publication: 2017 Oct 19.
Publication Year :
2018

Abstract

Purpose: To determine the impact of surgery and/or radiation therapy on distant metastatic sites (DMS) in children with stage IV rhabdomyosarcoma (RMS).<br />Methods: A retrospective chart review was conducted on all patients with stage IV RMS at Texas Children's Hospital from 1992 to 2012. Data analyzed included age, gender, primary site, histologic subtype, number and sites of metastases, treatment including local therapy to DMS, and Oberlin score.<br />Results: The 5-year progression-free survival (PFS) and overall survival (OS) rates were 20% and 25%. The 5-year PFS in patients receiving local therapy to all DMS (n = 16) and to less than all DMS (n = 19) was 31.3% versus 0% (P = 0.002), whereas the 5-year OS was 37.3% versus 0% (P < 0.001), respectively. The 5-year PFS in patients with isolated lung metastasis versus other types of metastasis was 29% versus 7% (P = n.s.), whereas the 5-year OS was 43% versus 10% (P = 0.01). The 5-year pulmonary local control was improved by the use of whole lung irradiation (WLI; 56% vs. 10%, P = 0.03).<br />Conclusions: Local treatment to all metastatic sites was associated with improved PFS and OS at 5 years. The use of WLI improved pulmonary control in patients with lung metastasis. We recommend an aggressive approach including local therapy to DMS in children with stage IV RMS.<br /> (© 2017 Wiley Periodicals, Inc.)

Details

Language :
English
ISSN :
1545-5017
Volume :
65
Issue :
2
Database :
MEDLINE
Journal :
Pediatric blood & cancer
Publication Type :
Academic Journal
Accession number :
29049857
Full Text :
https://doi.org/10.1002/pbc.26859